Unclaimed
Matthew Smeltzer
Is this your partnering profile? Claim & update it for free.
This profile was programmatically compiled from public sources. Take control to ensure accuracy, share updates, and connect with industry R&D teams.
About
Matthew Smeltzer advances population-based and real-world evidence in thoracic oncology, focusing on biomarker testing adoption, screening effectiveness, surgical quality standards, and disparities. Collaborates with IASLC and health systems to translate data into measurable improvements in lung cancer care.
Partnering listings
Learn more
No Partnering listings yet
This innovator has not added partnering listings yet. For now, explore their publications, funding, and other profile details to identify promising topics to connect on.
PT1.03.04 VIKTOR - the Virtual International Knowledgebase for Thoracic Oncology Research of the IASLC
2025
P1.17.24 Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes
2025
OA11.03 The Survival Impact of Subdividing Clinical and Pathologic N2 Descriptors in a Population-Based Surgical Cohort
2025
EP.06.53 c-MET Expression in Non-Squamous NSCLC: Molecular Correlation and Interobserver and Intersample Concordance on Scoring
2025
Impact of oncology second opinion consultation on anxiety levels and confidence in the organization.
2025
Pregnancy‐ and Disease‐Related Morbidity Among Medicaid Enrollees With Sickle Cell Disease
Pediatric Blood & Cancer
•2025
Biomarker testing of lung cancer in North America versus globally.
2025
Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.
2025
Commission on Cancer lung cancer surgery quality metric and overall survival in a population-based cohort.
2025
Real-world (rw) study to identify disparities in outcomes for patients (pts) with early-stage resected NSCLC who received biomarker-targeted adjuvant treatment (BTRx).
2025
1711 c-MET Expression in Lung Adenocarcinoma: Molecular Correlation and Interobserver and Intersample Reproducibility on Scoring
2025
101P: European results from the 2024 International Association for the Study of Lung Cancer (IASLC) global survey on biomarker testing
2025
P2.04B.14 Barriers to Maximal Screening Impact in Persons Diagnosed with Lung Cancer in a Prospective Cohort
2024
MA18.07 Missing Variables and the Utility of Lung Cancer and Lung Nodule Risk Calculators
2024
EP.07D.03 A Quality Improvement Initiative to Address Biomarker Testing and Quality of Care Delivery for Early-Stage NSCLC at 3 Cancer Centers in the US
2024
OA17.03 Missed Opportunities for Early Lung Cancer Detection in a Multi-Disciplinary Thoracic Oncology Clinic Cohort
2024
EP.07D.04 Outcomes with Evolving Patterns of Neoadjuvant Therapy: A Population-Based Analysis
2024
No funding yet
This innovator hasn't added funding yet. In the meantime, you might want to explore their publications, patents, and other profile details.
No patents yet
This innovator hasn't added patents yet. In the meantime, you might want to explore their publications, funding, and other profile details.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.